FDA Unveils Results of Largest-Ever Infant Formula Safety Study The U.S. Food and Drug Administration announced on April 29, 2026, the findings of its most extensive examination to date of chemical contaminants in infant formula sold across the country. The agency emphasized that while breast milk remains the ideal nutritional source for infants, millions of parents rely on formula, and the results of this comprehensive testing underscore the importance of maintaining strict safety standards. Health and Human Services Secretary Robert F. Kennedy, Jr., highlighted that the study involved testing more than 300 infant formula samples, representing a wide range of products available at retail locations nationwide. These samples were analyzed for over 120,000 data points, covering contaminants such as lead, mercury, cadmium, arsenic, pesticides (including glyphosate and glufosinate), per- and polyfluoroalkyl substances (PFAS), and phthalates. The testing included powders, ready-to-feed liquids, and concentrated liquids, all rigorously evaluated in FDA laboratories. Kennedy stated, “We tested more infant formula than ever before, and the results are clear: most products meet a high safety standard—but even small exposures matter for newborns.” He reiterated the agency’s commitment to holding manufacturers accountable and providing parents with transparent, reliable information to ensure the safety of their children. FDA Commissioner Marty Makary, M.D., M.P.H., added that the findings were encouraging, noting that an overwhelming majority of samples had undetectable or very low levels of contaminants. He emphasized the agency’s ongoing efforts to advance formula innovation and safety, stating, “The results of this study are encouraging.#fda #marty_makary #robert_f_kennedy #kyle_diamantas #operation_stork_speed
Novo Nordisk ends legal proceedings against Hims & Hers Hims & Hers shares surged after Novo Nordisk announced it would drop its patent infringement lawsuit against the telehealth provider. The decision followed an agreement between the two companies, which includes Hims offering Novo’s branded weight-loss drugs at the same price as other telehealth platforms and ceasing to advertise compounded GLP-1 drugs. Novo Nordisk CEO Mike Doustdar stated the legal case would be dropped, though the company reserved the right to revisit it if necessary. The agreement also involves Hims selling injectable and oral semaglutide, marketed as Ozempic and Wegovy, through its platform at prices comparable to other telehealth services. Hims will no longer promote compounded versions of GLP-1 drugs, which are unapproved by the FDA. The move comes after Novo accused Hims of selling counterfeit versions of Wegovy at a significantly lower price, which sparked backlash from both the company and the U.S. Food and Drug Administration. Hims’ shares rose over 40% in early trading, while Novo’s stock gained 2.1%. The FDA’s commissioner, Marty Makary, praised the agreement, emphasizing that Hims will provide affordable, FDA-approved medications and limit compounded drugs to rare cases. Makary noted that Hims’ shift away from unapproved compounded products aligns with regulatory efforts to curb illegal compounding practices. The dispute began in February when Novo sued Hims for selling a copycat version of Wegovy at $49, far below the branded price. Hims quickly halted the sale after pressure from Novo and the FDA, which warned of potential legal violations. The FDA has since pledged to take action against compounding pharmacies and referred Hims to the Department of Justice for further review.#hims_hers #novonordisk #marty_makary #semaglutide #zepbound
